These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35513774)

  • 1. Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.
    Dadhania V; Gonzalez D; Yousif M; Cheng J; Morgan TM; Spratt DE; Reichert ZR; Mannan R; Wang X; Chinnaiyan A; Cao X; Dhanasekaran SM; Chinnaiyan AM; Pantanowitz L; Mehra R
    BMC Cancer; 2022 May; 22(1):494. PubMed ID: 35513774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
    Chaux A; Albadine R; Toubaji A; Hicks J; Meeker A; Platz EA; De Marzo AM; Netto GJ
    Am J Surg Pathol; 2011 Jul; 35(7):1014-20. PubMed ID: 21677539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.
    Schelling LA; Williamson SR; Zhang S; Yao JL; Wang M; Huang J; Montironi R; Lopez-Beltran A; Emerson RE; Idrees MT; Osunkoya AO; Man YG; Maclennan GT; Baldridge LA; Compérat E; Cheng L
    Hum Pathol; 2013 Oct; 44(10):2227-33. PubMed ID: 23850495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
    Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
    Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion.
    Sung JY; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Kang SY; Choi YL; Kwon GY
    J Clin Pathol; 2016 Jul; 69(7):586-92. PubMed ID: 26670747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.
    Williamson SR; Zhang S; Yao JL; Huang J; Lopez-Beltran A; Shen S; Osunkoya AO; MacLennan GT; Montironi R; Cheng L
    Mod Pathol; 2011 Aug; 24(8):1120-7. PubMed ID: 21499238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.
    Erak E; Oliveira LD; Mendes AA; Dairo O; Ertunc O; Kulac I; Baena-Del Valle JA; Jones T; Hicks JL; Glavaris S; Guner G; Vidal ID; Markowski M; de la Calle C; Trock BJ; Meena A; Joshi U; Kondragunta C; Bonthu S; Singhal N; De Marzo AM; Lotan TL
    Mod Pathol; 2023 Oct; 36(10):100247. PubMed ID: 37307876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry.
    Falzarano SM; Zhou M; Carver P; Tsuzuki T; Simmerman K; He H; Magi-Galluzzi C
    Virchows Arch; 2011 Oct; 459(4):441-7. PubMed ID: 21773753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-based detection of ERG rearrangement-positive prostate cancer.
    Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
    Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.
    Gopalan A; Leversha MA; Dudas ME; Maschino AC; Chang J; Al-Ahmadie HA; Chen YB; Tickoo SK; Reuter VE; Fine SW
    Histopathology; 2013 Aug; 63(2):279-86. PubMed ID: 23701505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
    Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.
    Guo CC; Zuo G; Cao D; Troncoso P; Czerniak BA
    Mod Pathol; 2009 Jul; 22(7):866-71. PubMed ID: 19396154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
    Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
    Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and clinical application of
    Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
    Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
    Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
    Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
    Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
    Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
    Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.